Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 14/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.47 |
| ▸ | INSR | P06213 | 2/20 | 0.47 |
| ▸ | GAK | O14976 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12067097 | 0.82 | TNNI3K (0.58) | EGFRBRAFTNNI3K | |
| SCHEMBL29110516 | 0.78 | L3MBTL1 (0.48) | EGFRERBB2ABL1ALDH1A1MAPT | |
| SCHEMBL29771427 | 0.78 | L3MBTL1 (0.48) | EGFRERBB2ABL1ALDH1A1MAPT | |
| SCHEMBL7022406 | 0.78 | EGFR (0.57) | KDRAURKARPS6KB1EGFRERBB2 | |
| Hydrochloric Acid SCHEMBL7017577 | 0.77 | EGFR (0.56) | KDRAURKARPS6KB1EGFRERBB2 | |
| SCHEMBL7023791 | 0.73 | EGFR (0.49) | KDRAURKARPS6KB1EGFRERBB2 | |
| Hydrochloric Acid SCHEMBL7021265 | 0.72 | FBP1 (0.48) | KDRAURKARPS6KB1EGFRERBB2 | |
| SCHEMBL29894409 | 0.71 | ABCG2 (0.76) | EGFRERBB2ABL1GAKFBP1 | |
| SCHEMBL183355 | 0.71 | ABCG2 (0.76) | EGFRERBB2ABL1GAKFBP1 | |
| SCHEMBL7022884 | 0.71 | EGFR (0.60) | KDRAURKAEGFRERBB2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3290666-B2 | — | — | 2002-06-10 | — | — | JP | claimed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | claimed |
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | ARNOLD LEE DANIEL (US) | 2002-04-18 | — | — | US | claimed |
| EP-0946554-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1999-10-06 | — | — | EP | claimed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | claimed |
| WO-1998023613-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | claimed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0831829-B1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6413971-B1 | ANTIPROLIFERATIVE, -CARCINOGENIC, -TUMOR AND -DIABETIC AGENTS; BINDING TO OR MODULATING THE HUMAN KINASE INSERT-DOMAIN-CONTAINING RECEPTOR (KDR) OR THE MURINE FETAL LIVER KINASE 1 (FLK-1) RECEPTOR; VASCULOGENESIS; ANGIOGENESIS | PFIZER INC | 2002-07-02 | — | — | US | disclosed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | disclosed |
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | ARNOLD LEE DANIEL (US) | 2002-04-18 | — | — | US | disclosed |
| EP-0946554-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998023613-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | REV1, DPYD, CCNA1 | KDR 1533/4885AURKA 251/4885RPS6KB1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.